Open AccessAlternate Day versus Once Daily Atorvastatin for Primary Prevention of (CHD) in Naïve Patients of Dyslipidemia
Author(s) -
Canna Jagdish Ghia,
Archana Sushil Panda,
Linesh R Khobragade,
Rajesh Kumar Jha,
Gautam Rambhad
Publication year - 2014
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2014/7359.4096
Subject(s) - atorvastatin , dyslipidemia , medicine , ldl cholesterol , hmg coa reductase , reductase , very low density lipoprotein , lipoprotein , low density lipoprotein , cholesterol , endocrinology , pharmacology , chemistry , biochemistry , enzyme , obesity
Statins (or HMG-CoA reductase inhibitors) have become drug of choice for raised Low-Density Lipoprotein Cholesterol (LDL-C) in treating. Of these, Atorvastatin, because of its prolonged 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibition has been considered for alternate day therapy in primary prevention of (CHD).